John Newell-Price

Has grant

Professor of Endocrinology

University of Sheffield
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Evaluating the implementation and uptake of waking Salivary Cortisone: a new home-based test for Adrenal Insufficiency

Open Date: 2026-01-01

Close Date: 2029-12-01

Grant: Close

Dissecting the Contribution of glucocorticoid metabolism in Mild Autonomous Cortisol Secretion: DC-MACS' MR/W015455/1

Open Date: 2023-05-01

Close Date: 2026-06-01

Articles (22)

Objective Mild autonomous cortisol secretion (MACS) is associated with increased cardiometabolic risk factors including hypertension, type 2 diabetes and dyslipidaemia. By using evening doses of metyrapone, a short‐acting 11‐β hydroxylase inhibitor, it has been shown that it is possible to reset the abnormal circadian cortisol rhythm in MACS. This study aimed to evaluate the tolerability and impact of this approach on cardiometabolic outcomes in patients with MACS. Design We conducted a single‐centre retrospective, longitudinal review of patients with MACS who received evening metyrapone (250–500 mg at 6 PM and 250 mg at 10 PM) to evaluate adverse events, tolerability, and cardiometabolic outcomes (systolic and diastolic blood pressure, HbA1c, weight and non‐HDL cholesterol) at 6 months, compared to controls. Age and sex‐matched controls were identified from patients with adrenal incidentalomas and non‐suppressed serum cortisol following 1 mg overnight dexamethasone suppression testing. Results Fifteen patients and 15 matched controls were identified. Over 6 months there were no adrenal crises. Metyrapone was stopped in 2/15 patients in view of side effects. In the metyrapone group compared to controls, there were significant decreases in systolic blood pressure (−17.7 (SE 5.8) vs. +8.7 (5.7)mmHg, p = 0.008, n = 9) and diastolic blood pressure (−9.9 (4.2) vs. +3.0 (3.6)mmHg, p = 0.024). The differences between groups for HbA1c, weight and non‐HDL cholesterol were not statistically significant. Conclusion Evening metyrapone was associated with significant reductions in systolic and diastolic blood pressure in patients with MACS, without causing adrenal insufficiency, indicating its potential safe clinical utility. A well‐powered, controlled, prospective study is needed to validate these findings and comprehensively investigate the broader metabolic outcomes.

Year:

2026

Medical treatment of hypercortisolism may be necessary for a high proportion of patients with Cushing syndrome (CS), including those who are not candidates for curative surgery. It may also be used in the presurgical period when hypercortisolism is severe, as long-term treatment following surgical failure or recurrence after surgery, or while waiting for the effects of pituitary radiation in Cushing disease. Currently available medical treatments include adrenal steroidogenesis inhibitors that block cortisol secretion (ketoconazole, levoketoconazole, metyrapone, osilodrostat, mitotane, and etomidate), drugs that modulate pituitary ACTH secretion (pasireotide and cabergoline), and drugs that block peripheral glucocorticoid receptors (mifepristone). In addition, there are other medical treatments in development that target pituitary signaling pathways, ACTH or its adrenal receptor, or the conversion of cortisol from cortisone by 11ßHSD1. Steroidogenesis inhibitors can be administered using either a titration or a block-and-replace approach. Titration requires adjusting the daily drug dose with the aim of normalizing circulating cortisol levels, whereas the block-and-replace strategy uses higher drug doses to fully suppress endogenous cortisol production, followed by glucocorticoid supplementation. In this review, we summarize the main indications for medical treatment in CS, the mechanism of drug action, efficacy, recommended doses, and safety of the currently available drugs, as well as potential future treatments. We also discuss titration and block-and-replace approaches for control of hypercortisolism and provide recommendations for the use and monitoring of medical treatment in CS, including patients with endogenous hypercortisolism in special situations such as pregnancy, cyclic CS, and mild autonomous cortisol secretion.

Year:

2026

Year:

2026

Parathyroid hormone-related peptide (PTHrP)-secreting pancreatic neuroendocrine tumours (Pan-NETs) are a rare cause of humoural hypercalcaemia of malignancy (HCM). We report two contrasting cases of metastatic well-differentiated PTHrP-secreting Pan-NETs (WHO grade 2; Ki-67: 7 and 8%, respectively), highlighting the variability in disease progression, response to multiple treatment modalities, and long-term outcomes. The first patient, a 55-year-old woman with mild hypercalcaemia who was largely asymptomatic except for a persistent dry cough at presentation, achieved stable disease control following eight years of treatment with somatostatin analogues (SSAs), peptide receptor radionuclide therapy (PRRT), and chemotherapy. During a prolonged period of uncontrolled hypercalcaemia prior to chemotherapy, she developed rapid bilateral hip osteoarthrosis and tumour calcification, a rare complication from long-standing calcium elevation. The second patient, a 34-year-old woman, had a more aggressive disease course, requiring multiple hospital admissions for refractory moderate-to-severe hypercalcaemia and variceal bleeding. Despite initial tumour stabilisation following PRRT, she developed refractory hypercalcaemia, demonstrating only partial response to zoledronate, high-dose denosumab, and maximal somatostatin analogue therapy, and ultimately succumbed to progressive disease and metabolic deterioration. These cases underscore the heterogeneity of PTHrP-secreting Pan-NETs and the challenges in optimising treatment strategies, given the lack of data on the optimal sequencing of therapies. Notably, calcium can serve as a reliable tumour marker for disease control, with persistent severe hypercalcaemia being a potential prognostic factor of poor outcome in patients with PTHrP-related hypercalcaemia. International collaboration and knowledge exchange are needed to ascertain the most effective management of this rare functional syndrome. Learning points Consider PTHrP secretion in the context of hypercalcaemia in Pan-NETs. Calcium level can serve as a tumour marker in patients with PTHrP-related hypercalcaemia for assessing treatment response, disease progression, and tumour aggressiveness, with persistent hypercalcaemia being a prognostic factor for poor outcome. Hypercalcaemia may be resistant to standard treatments, and higher doses of denosumab may be necessary to achieve adequate control. An individualised multimodal treatment approach, including SSAs, PRRT, targeted therapy, chemotherapy, or a combination thereof, should be utilised to control PTHrP-secreting Pan-NETs. Although the optimal sequencing of these therapies remains unclear, multidisciplinary team discussions and shared decision-making are essential in managing such complex cases.

Year:

2026

Year:

2026

Introduction Adrenal incidentalomas (AI) are commonly found on imaging done for indications other than to assess the adrenal glands. Prevalence increases with age and is around 10% in people over 80 years. The majority of AIs are benign adenomas, with 20%−50% exhibiting mild autonomous cortisol secretion (MACS). Clinical guidelines recommend the use of dexamethasone to improve outcomes in patients with COVID‐19 requiring oxygen. Hypothesis Benign adrenal adenomas protect against severe COVID‐19. Methods Reports for all computed tomography pulmonary angiogram (CTPA) scans at Sheffield Teaching Hospitals between 11 March 2020 and 10 November 2021 were assessed for details of AI. Scan requests mandated recording COVID‐19 status. Patients with a positive COVID‐19 test within 2 weeks before the CTPA were classed as COVID‐19 positive for the analyses. Duplicate scans were removed. Results A total of 4307 CTPA scans were included. The median age was 65 (IQR 49−77) and the majority of patients were female (55.0%). Seventy‐six (1.76%) patients had a benign adenoma. COVID‐19 positivity was found in 897 (20.8%). The presence of a benign adenoma was associated with a 70% reduced odds of being COVID‐19 positive (aOR 0.30, 95% CI 0.12−0.74, p = 0.01), adjusting for age and sex. Conclusion Prevalence of adrenal adenoma was associated with significantly reduced odds of being SARS‐CoV2 positive in an inpatient cohort. Secretion of mild excess cortisol (MACS) may be protective against developing severe COVID‐19.

Year:

2026

Year:

2026

Year:

2026

Objective Surveillance is often adopted for asymptomatic non-functioning pituitary macroadenomas (macroNFPAs). Due to low-quality evidence, uncertainty remains on optimal frequency of imaging/biochemical monitoring and indications for surgery. We assessed the natural history and outcomes of patients with macroNFPA who had monitoring as initial management choice from the UK NFPA Consortium. Design This was a multicentre, retrospective, cohort study involving 21 UK endocrine departments. Methods Clinical, imaging, and hormonal data of 949 patients followed up between January, 1, 2005 and March, 1, 2022 were analysed. Results Incidence rate for tumour enlargement was 9.8 per 100 patient-years (95% CI, 8.8-10.8), with cumulative probabilities 1.6%, 8.1%, 18.4%, 29.2%, and 43.6% at 6-month, 1-year, 2-year, 3-year, and 5-year follow-up, respectively; rates were higher in tumours abutting/displacing optic chiasm than those not in contact with it. Amongst macroNFPAs not in contact with optic chiasm showing enlargement within 6 months, none impacted visual fields. In tumours with enlargement and continued monitoring (median 2.6 years), further growth occurred in 60.5% (33.8% probability at 2 years), stability in 35.5%, and shrinkage in 4.0%. Rates of new pituitary hormone deficits were 4.0%-4.9%, mainly driven by tumour enlargement. After transsphenoidal surgery, rates of hypopituitarism reversal were 12%-17% and those of additional anterior pituitary hormone deficits were 12%-15% (permanent vasopressin deficiency 3.5%). Conclusions Our data provide evidence for monitoring protocols. MacroNFPAs not in contact with optic chiasm require less frequent imaging, and first follow-up scan can be delayed to 1 year. After first enlargement, variable tumour behaviour can occur. New hypopituitarism in stable tumours is rare, challenging necessity of regular pituitary function assessment.

Year:

2025

Background Replacement therapy with modified‐release hydrocortisone capsules (MRHC) restores the physiological circadian cortisol rhythm in congenital adrenal hyperplasia (CAH). Aims To determine the relative bioavailability of MRHC and evaluate an optimal protocol to switch CAH patients from standard therapy to MRHC. Methods (1): Crossover study in healthy participants comparing relative bioavailability of MRHC with immediate‐release hydrocortisone (IRHC). (2): Post hoc analysis of first 4 weeks of phase 3 MRHC study when CAH patients were switched to MRHC. Results Twenty‐four healthy male participants completed the relative bioavailability study: 20 mg MRHC showed comparable bioavailability to 20 mg IRHC tablets; mean AUC 0−inf was 2650 versus 2450 h*nmol/L, ratio of 108% (90% confidence interval (CI) 103%−113%). In the phase 3 study, 122 CAH patients were recruited of which 63 patients were managed with IRHC alone at baseline; 31 of 63 were randomised to continue IRHC and 32 of 63 were randomised to switch to MRHC on the same daily dose but given twice daily. At 4 weeks, a greater reduction in both the 09:00 h 17‐hydroxyprogesterone and androstenedione was observed in the MRHC group compared to the IRHC group; p < 0.001 and p = 0.01, respectively. Conclusions MRHC showed comparable bioavailability to IRHC based on cortisol AUC after 20 mg administration. Switching patients treated with IRHC to a twice daily MRHC regimen on the same daily dose (giving approximately two thirds of the dose at night) is an effective protocol for starting MRHC treatment.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Collaborators (31)

Alessandro Prete

University of Birmingham

UNITED KINGDOM
View details

Przemysław Witek

Professor, of Endocrinology, Head of the Department

Medical University of Warsaw

POLAND
View details

Paul Benjamin Loughrey

The Queen's University Belfast

UNITED KINGDOM
View details

Wiebke Arlt

Professor of Transdisciplinary Medicine and Head of Department

Imperial College London

UNITED KINGDOM
View details

Cristina Lamas Oliveira

F.E.A

University of Castilla-La Mancha

SPAIN
View details

Deborah Merke

Chief, Department of Pediatrics and Senior Investigator

National Institutes of Health

UNITED STATES
View details

NIKI KARAVITAKI

University of Birmingham

UNITED KINGDOM
View details

Angelica Lindén Hirschberg

Professor, MD, PhD

Karolinska Institutet

SWEDEN
View details

Jon Hazeldine

University of Birmingham

UNITED KINGDOM
View details

Marta Araujo Castro

HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL

SPAIN
View details

Jacques Drouin

Professeur-Chercheur titulaire

Université de Montréal

CANADA
View details

Andre Lacroix

Professor

Université de Montréal

CANADA
View details

Jeremy Dawson

Professor of Health Management

University of Sheffield

UNITED KINGDOM
View details

Simon Berry

University of Sheffield

UNITED KINGDOM
View details

Georgios Tsermoulas

University of Birmingham

UNITED KINGDOM
View details

Aled Rees

Professor of Endocrinology

Cardiff University

UNITED KINGDOM
View details

Nils Krone

Professor of Paediatric Endocrinology, PI

University of Sheffield

UNITED KINGDOM
View details

Rosario Pivonello

-

ITALY
View details

Joseph G Verbalis

Georgetown University Medical Center

UNITED STATES
View details

Daniel Hind

Associate Professor in Health and Social Care Evaluation

University of Leeds

UNITED KINGDOM
View details

Saurabh Sinha

University of Sheffield

UNITED KINGDOM
View details

Mark Gurnell

University of Cambridge

UNITED KINGDOM
View details

Olaf M Dekkers

Leiden University Medical Center

NETHERLANDS
View details

Miguel Debono

University of Sheffield

UNITED KINGDOM
View details

jonathan wadsley

University of Sheffield

UNITED KINGDOM
View details

Angela, E Taylor

University of Birmingham

UNITED KINGDOM
View details

Maria Fleseriu

Oregon Health & Science University

UNITED STATES
View details

Thierry Brue

Professeur des Universités-Praticien Hospitalier (PU-PH)

Aix-Marseille University

FRANCE
View details

Ahmed Iqbal

Senior Clinical Lecturer and Honorary Consultant in Diabetes

University of Sheffield

UNITED KINGDOM
View details

Alberto M. Pereira

Professor of Medicine, head of department

University of Amsterdam

NETHERLANDS
View details

Neil Lawrence

University of Sheffield

UNITED KINGDOM
View details